DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
The 28-month Wegovy shortage ended this week. Compounders now face 60-day wind-down. What this means for the ~1.2M patients on compounded semaglutide — and your prescription path forward.
FDA removed semaglutide from the drug shortage list on May 4. Per FDC Act section 503A, compounding pharmacies have 60 days to wind down semaglutide preparations. We estimate 1.2M patients on compounded semaglutide will need to transition. Three paths: brand Wegovy via insurance, NovoCare cash ($499), or LillyDirect tirzepatide ($549).